Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome831
Zolbetuximab treatment in metastatic gastric cancer570
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity550
Hybrid EASL Congress 2023545
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology498
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection473
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis445
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa404
Mapping neuroimmune interactions in the gut390
Digestive Disease Week 2022372
The future of treating pancreatic exocrine insufficiency356
Western lifestyle, metaflammation and the cell of origin of colon cancer330
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection265
2023 FDA approvals in gastroenterology and hepatology254
Advancing nutrition science for global health251
Black–White disparities across the colorectal cancer care continuum in the USA249
Large language models for clinical decision support in gastroenterology and hepatology237
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed216
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis214
Nomenclature of HBV core protein-targeting antivirals205
Artificial intelligence and automation in endoscopy and surgery198
Oral microbiome therapy efficacious for recurrent C. difficile infection197
Wound healing in the colon192
Hepatic IRF3 in glucose intolerance188
New understanding of hepatobiliary MRI187
Metastatic pancreatic cancer and the liver179
GWAS reveals variants for alcohol-related hepatocellular carcinoma176
Lessons from incretin-based therapy in MASH and obesity174
Food as medicine in gastrointestinal cancer therapy171
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges166
Inflammatory bowel disease in pregnancy and breastfeeding162
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract158
A crucial Fusobacterium nucleatum clade in colorectal cancer150
The global burden of coeliac disease: opportunities and challenges149
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation146
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases142
Hepatocyte-derived biomarkers in alcohol-related cirrhosis137
Integrated systems approach to identify environmental factors in intestinal inflammation135
Characterizing the genomic landscape of colorectal cancer134
Metabolic diseases in the East Asian populations133
Medical therapy of paediatric inflammatory bowel disease133
Estimating dietary intake from human stool DNA132
Probiotics for preterms: sharing complex decision-making130
HDCA ameliorates NAFLD in mice129
Proteases in intestinal health and disease127
Liver, ageing and disease124
Preventing the progression of cirrhosis to decompensation and death120
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment114
Implications of the evolving knowledge of the genetic architecture of MASLD114
SSRIs and depression: role of gut–brain communication111
The path to successful hepatitis C elimination in Spain110
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook110
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease106
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management104
Current and future colorectal cancer screening strategies103
Human intestinal B cells in inflammatory diseases102
NAFLD prevalence in older patients with T2DM102
Phase III results for first-line treatment for metastatic colorectal cancer101
Author Correction: Hepatic immune regulation and sex disparities94
ECCO’2490
The future of pathology in gastroenterology and hepatology89
Microbiota and colorectal cancer — controlling for confounders challenges associations87
GLP1R agonists in NAFLD: a promising therapy on the horizon84
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’84
Enteric nervous system transfers stress to the gut83
Gut microbiome and autism spectrum disorder82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance79
Transforming the landscape of liver cancer detection and care78
Hepatic glucose metabolism in the steatotic liver77
Neutrophils as potential therapeutic targets in hepatocellular carcinoma73
0.042225122451782